The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma

Hanneke W. M. van Laarhoven*, Sarah Derks

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic


In the ASTRUM-007 randomized double-blind phase III study, Song et al.1 showed that the combination of PD-1 inhibitors with first-line fluoropyrimidine and platinum-based chemotherapy improves outcomes in PD-L1-overexpressing esophageal squamous cell carcinomas.
Original languageEnglish
Article number100990
JournalCell Reports Medicine
Issue number4
Publication statusPublished - 18 Apr 2023

Cite this